Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

April 30, 2019

Keytruda-Inlyta Combo Approved by FDA for Untreated Advanced Kidney Cancer

News

The U.S. Food and Drug Administration (FDA) has approved a combination of Keytruda (pembrolizumab) plus Inlyta (axitinib) for the initial treatment of patients with advanced renal cell carcinoma, the ... Read more

April 26, 2019April 29, 2019

PureTech Presents Data About Two Promising Anti-cancer Therapies

News

PureTech Health is developing two promising candidate therapies that target key immunosuppressive mechanisms in cancer and may be used against cancers that fail to respond to existing immunotherapy approaches. The ... Read more

March 27, 2019

Phase 2 Clinical Trial of CRS-207, Keytruda Combo for MPM is Discontinued

News

A combination of the immunotherapies Keytruda (pembrolizumab) and CRS-207 is safe, but has no evidence of clinical activity in adults with malignant pleural mesothelioma who failed prior lines of therapy, a ... Read more

March 22, 2019

FDA Approves Tecentriq/Chemo for Newly Diagnosed Extensive-stage SCLC

News

The U.S. Food and Drug Administration has approved the use of Tecentriq (atezolizumab) in combination with the chemotherapies Paraplatin (carboplatin) and etoposar for the initial treatment of extensive-stage small-cell lung ... Read more

March 20, 2019

EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC

News

The European Commission has approved a combination of Keytruda (pembrolizumab) plus standard chemotherapy for the initial treatment of metastatic squamous non-small cell lung cancer (NSCLC), Merck (known as MSD ... Read more

March 8, 2019

Phase 3 Keytruda Trial Fails Primary Objectives in Liver Cancer Patients Who Received Prior Nexavar

News

Immune checkpoint inhibitor Keytruda (pembrolizumab) did not significantly improve the survival outcomes of previously treated hepatocellular carcinoma patients on best supportive care, results from a Phase 3 trial show. ... Read more

February 27, 2019

FDA Approves Keytruda for Melanoma Patients After Tumor Resection

News

The U.S. Food and Drug Administration has approved the use of Keytruda (pembrolizumab) as a treatment for melanoma patients with stage 3 disease — cancer cells have spread to the ... Read more

February 22, 2019

Keytruda Better Than Chemotherapy for Untreated Advanced Merkel Cell Carcinomas, Phase 2 Trial Suggests

News

Patients with an aggressive kind of skin cancer called Merkel cell carcinoma appear to have better responses and live longer when given the PD-1 inhibitor Keytruda (pembrolizumab), compared to ... Read more

February 20, 2019

FDA Grants Priority Review to Keytruda-Inlyta Combo for Untreated, Advanced Kidney Cancer Patients

News

The U.S. Food and Drug Administration has granted priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for the initial treatment of ... Read more

February 12, 2019February 12, 2019

Bavencio Shows Promise in Phase 1 Trial of Heavily Treated Malignant Mesothelioma Patients

News

Immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant mesothelioma patients, according to a Phase 1 clinical trial. The treatment — ... Read more

Pin It on Pinterest